Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $4.00

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned an average recommendation of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $4.00.

A number of research firms have issued reports on MCRB. Chardan Capital restated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a report on Thursday, March 20th. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, The Goldman Sachs Group dropped their price target on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research report on Friday, March 14th.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds have recently made changes to their positions in MCRB. FMR LLC increased its stake in Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after acquiring an additional 140,096 shares during the period. Millennium Management LLC increased its position in shares of Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 788,762 shares during the period. Geode Capital Management LLC increased its position in shares of Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 543,469 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 15.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock worth $720,000 after purchasing an additional 117,107 shares during the period. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Trading Up 8.3 %

NASDAQ MCRB opened at $0.58 on Tuesday. The company has a market cap of $101.23 million, a P/E ratio of -2.52 and a beta of 2.54. Seres Therapeutics has a 1 year low of $0.46 and a 1 year high of $1.53. The company has a fifty day simple moving average of $0.73 and a 200 day simple moving average of $0.79.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.